Developer docs
API playgroundTry for free, no card

Search company profiles

EdenRoc Sciences

Full company profile

uuid0000xs1

Namestring
EdenRoc Sciences
Legal namestring
EdenRoc Sciences, LLC
Company typeenum
Private
Founded yearint
2016
Descriptiontext

EdenRoc Sciences, LLC is a privately-held life sciences holding and operating company headquartered in Worcester, Massachusetts (with a secondary office in Cambridge, Massachusetts), founded in 2016 and structured as a Delaware LLC. The company operates a portfolio of approximately ten autonomous subsidiaries spanning clinical-stage pharmaceuticals (Metro International Biotech, developing the world's most comprehensive proprietary NAD booster portfolio for rare mitochondrial diseases, acute kidney injury, long-haul COVID, neurodegenerative disease, diabetic neuropathy, and muscle endurance), multiomics tools (Cantata Bio, parent to Dovetail Genomics and Arc Bio, delivering NGS-based products for genome assembly, phasing, chromatin structure, and epigenomics), cell-free DNA sequencing for liquid biopsy (Claret Bioscience), advanced forensic DNA recovery from degraded samples (Astrea Forensics), biologic-based consumer care ingredients derived from a space-survivor Bacillus isolate (Delavie Sciences), US Government and biosecurity partnerships (Liberty Biosecurity), and IP holding entities for short RNA synthesis (UpRNA) and microarray-based pathogen detection (Revere Biosensors).

The company's business model is a holding company structure rather than a traditional product sales operation: EdenRoc founds or acquires subsidiaries based on novel science, often licensed from top universities, and supports each with shared parent-level functions including legal, HR, benefits, accounting, finance, IT, and business planning. Cross-portfolio collaboration is fostered through shared board oversight and parent-level equity grants to employees and advisors. Combined headcount exceeds 100 scientists and staff, supported by over 40 world-class advisors drawn from institutions including Harvard Medical School, MIT, Stanford, and the University of Michigan.

EdenRoc raises capital through private exempt securities offerings filed via SEC Form D under Rule 506(b), with three disclosed offerings between 2022 and 2024 totaling approximately $150 million in aggregate offering capacity. Revenue is not publicly disclosed, and pricing across subsidiary product lines is opaque. The company's leadership is anchored by founder and Chairman Edward Schulak and Vice Chairman Dr. David Sinclair (Harvard Medical School professor and co-Director of the Paul F. Glenn Center for the Biology of Aging Research), with Chairman Emeritus J. Taylor Crandall (Oak Hill Capital founding member) on the board.

Short descriptiontext

EdenRoc Sciences is a privately-held life sciences holding company that founds and operates autonomous subsidiaries across clinical-stage pharmaceuticals (NAD boosters), NGS-based multiomics tools, forensic DNA recovery, consumer care biologics, and government biosecurity. It serves pharma, research, law enforcement, consumer care, and US Government markets.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
life sciences portfolio, biotechnology holding company, clinical stage pharmaceuticals, genomic sequencing tools, forensic DNA services
Industry4 codes
PRIMARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAFAI
Microbiome Analytics, Sequencing & Bioinformatics Platforms
SECONDARYHLAGAJAM
Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAC
Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Software Publishers513210
  • Scientific Research and Development Services5417
SIC code4 codes
  • Services-Commercial Physical & Biological Research8731
  • Pharmaceutical Preparations2834
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Prepackaged Software7372
Product category
Biotechnology Holding Company
No data
Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

EdenRoc Sciences is a life sciences portfolio company that founds, owns, and operates autonomous biotech subsidiaries developing clinical-stage NAD-boosting pharmaceuticals, NGS-based multiomics and genomics tools, cell-free DNA liquid biopsy technologies, forensic DNA recovery services, space-derived biologic consumer care ingredients, RNA therapeutics synthesis platforms, and microarray-based pathogen detection technology. Each subsidiary commercializes its own products and services while EdenRoc provides shared corporate support and cross-subsidiary collaboration.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

EdenRoc Sciences is a life sciences portfolio/holding company structured as a platform of autonomous subsidiary companies, each focused on different biotechnology markets. The subsidiaries include: Metro International Biotech (clinical-stage pharmaceuticals developing NAD boosters for age-related and mitochondrial diseases); Cantata Bio (multiomics tools company parent to Dovetail Genomics and Arc Bio offering NGS-based products and services); Claret Bioscience (NGS tools for cell-free DNA analysis and liquid biopsy); Astrea Forensics (DNA technology services for degraded forensics samples); Delavie Sciences (consumer care ingredients including Bacillus Lysate); Liberty Biosecurity (US Government partnerships); UpRNA (RNA therapeutics IP); and Revere Biosensors (microarray technology for pathogen detection). The company supports subsidiaries with core business functions while fostering cross-collaboration through shared board oversight and equity grants.

Product and service10 records
1Metro International Biotech LLC (Metro)
CategoryClinical-stage pharmaceutical subsidiary
Description

Clinical-stage pharmaceutical company that has established the most comprehensive portfolio of proprietary NAD boosters in the world, developing compounds to treat rare mitochondrial diseases, acute kidney injury, long-haul COVID, neurodegenerative disease, diabetic neuropathy, and muscle endurance, with potential applications in renal failure, ophthalmic diseases, liver injuries, ischemic injuries, and neuromuscular disorders.

2Cantata Bio
CategoryMultiomics tools subsidiary
Description

Multiomics tools company delivering powerful, novel NGS-based products and services for researchers and clinicians, with integrated metagenomic workflows for microbial detection and quantification and unique long-range sequencing assays for genome assembly, phasing, chromatin structure, and epigenomics.

3Dovetail Genomics
CategoryGenomics tools subsidiary
Description

NGS-based genomics tools and services providing long-range sequencing assays for industry-leading genome assembly, phasing, chromatin structure, and epigenomics.

4Arc Bio
CategoryMicrobial detection subsidiary
Description

NGS-based products and services focused on enabling researchers and clinicians to solve challenging scientific problems in human disease and agricultural sustainability through microbial detection and quantification.

5Claret Bioscience, LLC
CategoryCell-free DNA / liquid biopsy tools subsidiary
Description

Commercial-stage biotechnology company that developed novel technologies for improving NGS-based discovery from cell-free DNA, providing NGS tools and software that exploit novel signals discovered at native termini of DNA fragments, including in single DNA strands, for use in liquid biopsy applications.

6Astrea Forensics, LLC
CategoryForensic DNA services subsidiary
Description

Biotechnology company focused on applying the most advanced DNA technology to forensics casework, offering services to law enforcement and related agencies for recovering, sequencing, and genotyping DNA from degraded forensics samples that fail conventional testing, providing genome-wide solutions for investigative genetic genealogy.

7Delavie Sciences
CategoryConsumer care ingredients subsidiary
Description

Pioneer in cutting-edge ingredients and products for the consumer care industry; produces Bacillus Lysate, a premiere ingredient derived from a unique biological isolate that survived prolonged exposure on the exterior of the International Space Station, with demonstrated SPF enhancement in sunscreen formulations and antioxidant properties for anti-aging serum applications.

8Liberty Biosecurity
CategoryGovernment biosecurity partnerships subsidiary
Description

Government partnerships subsidiary developing relationships with the US Government and international partners to bring life sciences expertise to unclassified and classified national security challenges while raising non-dilutive funding.

9UpRNA
CategoryRNA therapeutics IP holding subsidiary
Description

IP holding company with technology enabling researchers working on experimental RNA therapeutics to design and synthesize short RNAs affordably and on demand, removing cost barriers in siRNA therapeutic development.

10Revere Biosensors
CategoryMicroarray detection IP holding subsidiary
Description

Biotechnology IP holding company with technology related to novel microarray design, fabrication, and use based on Illumina's bead array technology with enhancements on speed and cost for rapid point-of-care detection and characterization of organisms including pathogens and microbiomes.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Biotech venture creation firm that founds and operates multiple platform companies (e.g., Moderna, Generate Biomedicines) from licensed academic science. Closest analog to EdenRoc's holding-company model of founding autonomous subsidiaries around novel university IP and supporting them with centralized resources.

TypeDirect peer
Description

Long-standing biotech creation and investment firm that founds and builds multiple life sciences companies from university-licensed technology. Operates a similar multi-subsidiary model focused on aging, genomics, and therapeutics, mirroring EdenRoc's portfolio construction approach.

TypeDirect peer
Description

Public platform biotech that develops biological products across multiple end markets through a centralized R&D engine and subsidiary-like programs. Comparable to EdenRoc in operating multiple biotech programs under one umbrella with shared scientific infrastructure.

TypeBroad incumbent
Description

Leading provider of single-cell and multiomics tools (Chromium, Visium, Xenium) widely used in genomics research. Comparable to Cantata Bio's Dovetail/Arc Bio multiomics offerings as a competitor and as a market-sizing reference for the multiomics tools opportunity.

TypeDirect peer
Description

Leading liquid biopsy company commercializing cfDNA-based cancer diagnostics. Most direct commercial-stage peer to Claret Bioscience's cfDNA/liquid biopsy technology and addresses the same translational research and clinical market.

TypeBroad incumbent
Description

Dominant NGS platform vendor whose bead array technology underpins Revere Biosensors' microarray IP. As the broader sequencing ecosystem leader, Illumina sets competitive dynamics for Cantata Bio's long-range sequencing and Claret's cfDNA assays.

TypeDirect peer
Description

Commercial-stage liquid biopsy and cfDNA diagnostics company (Signatera, Vantage) focused on oncology and reproductive health. Directly comparable to Claret Bioscience as a cfDNA platform competing for translational and clinical research customers.

TypeDirect peer
Description

Long-read sequencing platform company (HiFi sequencing) competing in genome assembly and structural variant markets that Dovetail Genomics and Cantata Bio also serve. Strong technological overlap for genome assembly, phasing, and epigenomics applications.

TypeBroad incumbent
Description

Provider of spatial biology and multiomics research tools (GeoMx, CosMx, nCounter) serving the same translational and clinical research customer base as Cantata Bio. Comparable as a broader multiomics platform competitor.

TypeEmerging player
Description

Machine learning-driven drug discovery company building a platform of therapeutic programs from biological data. Comparable to EdenRoc's model of operating multiple programs under shared infrastructure, with a sharper focus on AI-enabled small-molecule discovery.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile8 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries10 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds12 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

EdenRoc Sciences

Biotechnology Holding Companyedenrocsciences.com

EdenRoc Sciences is a privately-held life sciences holding company that founds and operates autonomous subsidiaries across clinical-stage pharmaceuticals (NAD boosters), NGS-based multiomics tools, forensic DNA recovery, consumer care biologics, and government biosecurity. It serves pharma, research, law enforcement, consumer care, and US Government markets.

What EdenRoc Sciences does

EdenRoc Sciences, LLC is a privately-held life sciences holding and operating company headquartered in Worcester, Massachusetts (with a secondary office in Cambridge, Massachusetts), founded in 2016 and structured as a Delaware LLC. The company operates a portfolio of approximately ten autonomous subsidiaries spanning clinical-stage pharmaceuticals (Metro International Biotech, developing the world's most comprehensive proprietary NAD booster portfolio for rare mitochondrial diseases, acute kidney injury, long-haul COVID, neurodegenerative disease, diabetic neuropathy, and muscle endurance), multiomics tools (Cantata Bio, parent to Dovetail Genomics and Arc Bio, delivering NGS-based products for genome assembly, phasing, chromatin structure, and epigenomics), cell-free DNA sequencing for liquid biopsy (Claret Bioscience), advanced forensic DNA recovery from degraded samples (Astrea Forensics), biologic-based consumer care ingredients derived from a space-survivor Bacillus isolate (Delavie Sciences), US Government and biosecurity partnerships (Liberty Biosecurity), and IP holding entities for short RNA synthesis (UpRNA) and microarray-based pathogen detection (Revere Biosensors).

The company's business model is a holding company structure rather than a traditional product sales operation: EdenRoc founds or acquires subsidiaries based on novel science, often licensed from top universities, and supports each with shared parent-level functions including legal, HR, benefits, accounting, finance, IT, and business planning. Cross-portfolio collaboration is fostered through shared board oversight and parent-level equity grants to employees and advisors. Combined headcount exceeds 100 scientists and staff, supported by over 40 world-class advisors drawn from institutions including Harvard Medical School, MIT, Stanford, and the University of Michigan.

EdenRoc raises capital through private exempt securities offerings filed via SEC Form D under Rule 506(b), with three disclosed offerings between 2022 and 2024 totaling approximately $150 million in aggregate offering capacity. Revenue is not publicly disclosed, and pricing across subsidiary product lines is opaque. The company's leadership is anchored by founder and Chairman Edward Schulak and Vice Chairman Dr. David Sinclair (Harvard Medical School professor and co-Director of the Paul F. Glenn Center for the Biology of Aging Research), with Chairman Emeritus J. Taylor Crandall (Oak Hill Capital founding member) on the board.

EdenRoc Sciences firmographics

Firmographics
Name
EdenRoc Sciences
Legal name
EdenRoc Sciences, LLC
Website
https://edenrocsciences.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
EdenRoc Sciences is a privately-held life sciences holding company that founds and operates autonomous subsidiaries across clinical-stage pharmaceuticals (NAD boosters), NGS-based multiomics tools, forensic DNA recovery, consumer care biologics, and government biosecurity. It serves pharma, research, law enforcement, consumer care, and US Government markets.
Ownership category
akta.pro rank

EdenRoc Sciences industry classification

Industry
Product category
Biotechnology Holding Company
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Software Publishers (513210), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835), Services-Prepackaged Software (7372)
akta.pro industry
PRIMARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAFAI
Microbiome Analytics, Sequencing & Bioinformatics Platforms
SECONDARYHLAGAJAM
Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAJAC
Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • Life sciences portfolio
  • Biotechnology holding company
  • Clinical stage pharmaceuticals
  • Genomic sequencing tools
  • Forensic DNA services

Where EdenRoc Sciences is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices2 records

Markets served

EdenRoc Sciences business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

EdenRoc Sciences product offering

Product offering

Core offering

EdenRoc Sciences is a life sciences portfolio company that founds, owns, and operates autonomous biotech subsidiaries developing clinical-stage NAD-boosting pharmaceuticals, NGS-based multiomics and genomics tools, cell-free DNA liquid biopsy technologies, forensic DNA recovery services, space-derived biologic consumer care ingredients, RNA therapeutics synthesis platforms, and microarray-based pathogen detection technology. Each subsidiary commercializes its own products and services while EdenRoc provides shared corporate support and cross-subsidiary collaboration.

Product overview

EdenRoc Sciences is a life sciences portfolio/holding company structured as a platform of autonomous subsidiary companies, each focused on different biotechnology markets. The subsidiaries include: Metro International Biotech (clinical-stage pharmaceuticals developing NAD boosters for age-related and mitochondrial diseases); Cantata Bio (multiomics tools company parent to Dovetail Genomics and Arc Bio offering NGS-based products and services); Claret Bioscience (NGS tools for cell-free DNA analysis and liquid biopsy); Astrea Forensics (DNA technology services for degraded forensics samples); Delavie Sciences (consumer care ingredients including Bacillus Lysate); Liberty Biosecurity (US Government partnerships); UpRNA (RNA therapeutics IP); and Revere Biosensors (microarray technology for pathogen detection). The company supports subsidiaries with core business functions while fostering cross-collaboration through shared board oversight and equity grants.

Differentiator

Problem solved

Functional benefit

Products and services

  • Metro International Biotech LLC (Metro) Clinical-stage pharmaceutical company that has established the most comprehensive portfolio of proprietary NAD boosters in the world, developing compounds to treat rare mitochondrial diseases, acute kidney injury, long-haul COVID, neurodegenerative disease, diabetic neuropathy, and muscle endurance, with potential applications in renal failure, ophthalmic diseases, liver injuries, ischemic injuries, and neuromuscular disorders.
  • Cantata Bio Multiomics tools company delivering powerful, novel NGS-based products and services for researchers and clinicians, with integrated metagenomic workflows for microbial detection and quantification and unique long-range sequencing assays for genome assembly, phasing, chromatin structure, and epigenomics.
  • Dovetail Genomics NGS-based genomics tools and services providing long-range sequencing assays for industry-leading genome assembly, phasing, chromatin structure, and epigenomics.
  • Arc Bio NGS-based products and services focused on enabling researchers and clinicians to solve challenging scientific problems in human disease and agricultural sustainability through microbial detection and quantification.
  • Claret Bioscience, LLC Commercial-stage biotechnology company that developed novel technologies for improving NGS-based discovery from cell-free DNA, providing NGS tools and software that exploit novel signals discovered at native termini of DNA fragments, including in single DNA strands, for use in liquid biopsy applications.
  • Astrea Forensics, LLC Biotechnology company focused on applying the most advanced DNA technology to forensics casework, offering services to law enforcement and related agencies for recovering, sequencing, and genotyping DNA from degraded forensics samples that fail conventional testing, providing genome-wide solutions for investigative genetic genealogy.
  • Delavie Sciences Pioneer in cutting-edge ingredients and products for the consumer care industry; produces Bacillus Lysate, a premiere ingredient derived from a unique biological isolate that survived prolonged exposure on the exterior of the International Space Station, with demonstrated SPF enhancement in sunscreen formulations and antioxidant properties for anti-aging serum applications.
  • Liberty Biosecurity Government partnerships subsidiary developing relationships with the US Government and international partners to bring life sciences expertise to unclassified and classified national security challenges while raising non-dilutive funding.
  • UpRNA IP holding company with technology enabling researchers working on experimental RNA therapeutics to design and synthesize short RNAs affordably and on demand, removing cost barriers in siRNA therapeutic development.
  • Revere Biosensors Biotechnology IP holding company with technology related to novel microarray design, fabrication, and use based on Illumina's bead array technology with enhancements on speed and cost for rapid point-of-care detection and characterization of organisms including pathogens and microbiomes.

Companies that use EdenRoc Sciences

Customer profile

Segments5 records

Ideal customer profiles8 records

EdenRoc Sciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

EdenRoc Sciences partnerships and signals

Strategic signal

Scale indicators5 records

Recent moves8 records

Expansion highlights6 records

EdenRoc Sciences competitors and assessment

Company assessment

Direct peers

  • Flagship Pioneering: Biotech venture creation firm that founds and operates multiple platform companies (e.g., Moderna, Generate Biomedicines) from licensed academic science. Closest analog to EdenRoc's holding-company model of founding autonomous subsidiaries around novel university IP and supporting them with centralized resources.
  • ARCH Venture Partners: Long-standing biotech creation and investment firm that founds and builds multiple life sciences companies from university-licensed technology. Operates a similar multi-subsidiary model focused on aging, genomics, and therapeutics, mirroring EdenRoc's portfolio construction approach.
  • Ginkgo Bioworks: Public platform biotech that develops biological products across multiple end markets through a centralized R&D engine and subsidiary-like programs. Comparable to EdenRoc in operating multiple biotech programs under one umbrella with shared scientific infrastructure.
  • Guardant Health: Leading liquid biopsy company commercializing cfDNA-based cancer diagnostics. Most direct commercial-stage peer to Claret Bioscience's cfDNA/liquid biopsy technology and addresses the same translational research and clinical market.
  • Natera: Commercial-stage liquid biopsy and cfDNA diagnostics company (Signatera, Vantage) focused on oncology and reproductive health. Directly comparable to Claret Bioscience as a cfDNA platform competing for translational and clinical research customers.
  • Pacific Biosciences: Long-read sequencing platform company (HiFi sequencing) competing in genome assembly and structural variant markets that Dovetail Genomics and Cantata Bio also serve. Strong technological overlap for genome assembly, phasing, and epigenomics applications.

Broad incumbents

  • 10x Genomics: Leading provider of single-cell and multiomics tools (Chromium, Visium, Xenium) widely used in genomics research. Comparable to Cantata Bio's Dovetail/Arc Bio multiomics offerings as a competitor and as a market-sizing reference for the multiomics tools opportunity.
  • Illumina: Dominant NGS platform vendor whose bead array technology underpins Revere Biosensors' microarray IP. As the broader sequencing ecosystem leader, Illumina sets competitive dynamics for Cantata Bio's long-range sequencing and Claret's cfDNA assays.
  • NanoString Technologies: Provider of spatial biology and multiomics research tools (GeoMx, CosMx, nCounter) serving the same translational and clinical research customer base as Cantata Bio. Comparable as a broader multiomics platform competitor.

Emerging players

  • Insitro: Machine learning-driven drug discovery company building a platform of therapeutic programs from biological data. Comparable to EdenRoc's model of operating multiple programs under shared infrastructure, with a sharper focus on AI-enabled small-molecule discovery.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

EdenRoc Sciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

EdenRoc Sciences leadership team

Management profile

Number of profiles

Profiles11 records

EdenRoc Sciences subsidiaries and ownership

Company hierarchy

Subsidiaries10 records

EdenRoc Sciences funding detail

Funding detail

Funding overview

Funding rounds12 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

EdenRoc Sciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EdenRoc Sciences

What does EdenRoc Sciences do?

EdenRoc Sciences is a life sciences portfolio company that founds, owns, and operates autonomous biotech subsidiaries developing clinical-stage NAD-boosting pharmaceuticals, NGS-based multiomics and genomics tools, cell-free DNA liquid biopsy technologies, forensic DNA recovery services, space-derived biologic consumer care ingredients, RNA therapeutics synthesis platforms, and microarray-based pathogen detection technology. Each subsidiary commercializes its own products and services while EdenRoc provides shared corporate support and cross-subsidiary collaboration.

Is EdenRoc Sciences a public or private company?

EdenRoc Sciences is a private company. It is classified as venture growth investor backed and is currently operating.

When was EdenRoc Sciences founded?

EdenRoc Sciences was founded in 2016. It employs 11 to 50 people.

Where is EdenRoc Sciences based?

EdenRoc Sciences is headquartered in Cambridge, United States, in the North America region.

Who are EdenRoc Sciences's main competitors?

Direct peers on record are Flagship Pioneering, ARCH Venture Partners, Ginkgo Bioworks, Guardant Health, Natera and Pacific Biosciences. Broad incumbents are 10x Genomics, Illumina and NanoString Technologies. Insitro is listed as an emerging player.

Does EdenRoc Sciences have an API?

No public API is recorded for EdenRoc Sciences.

What industry is EdenRoc Sciences in?

EdenRoc Sciences's product category is Biotechnology Holding Company. Its primary akta.pro industry code is HLAGAJAD, Bioinformatics & Multi-omics Analysis Software, with a secondary code of HLAAAFAI, Microbiome Analytics, Sequencing & Bioinformatics Platforms. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
SecSEC FORM DEdenRoc Sciences LLC filed a Form D with the U.S. Securities and Exchange Commission to announce an exempt offering of equity securities under Rule 506(b). The company is raising up to $50 million, with $2.75 million already sold to three investors as of November 7, 2024.SecSEC FORM DEdenRoc Sciences LLC filed a Form D with the SEC to report an exempt securities offering under Rule 506(b). The company raised a total of $64,175,000 from 50 investors for working capital purposes. The filing was signed by Treasurer and VP of Finance Christopher McDoniel on July 16, 2024.SecSEC FORM DEdenRoc Sciences LLC filed a Form D with the Securities and Exchange Commission, indicating an exempt offering of securities. The total amount sold from this offering is $55,525,000, with the issuance intended to last more than one year. The proceeds are expected to be used for working capital purposes.SecSEC FORM DEdenRoc Sciences LLC filed a Form D with the U.S. Securities and Exchange Commission to report an exempt offering of securities under Rule 506(b). The filing discloses a total offering amount of $35,900,016, with proceeds designated for working capital purposes. The document lists several executive officers and directors associated with the Cambridge-based biotechnology company.SecSEC FORM DEdenRoc Sciences LLC filed a Form D with the SEC for an exempt offering of equity securities under Rule 506(b), with total sales amounts reaching $27,600,016. The company, organized in Delaware and based in Michigan, intends to use the proceeds for working capital purposes. This filing was signed by General Counsel Mathew Easterday on January 18, 2022.PR NewswireArc Bio Established to Develop NGS Tools to Revolutionize Infectious Disease FieldArc Bio announced the launch of Galileo™ AMR, a proprietary antimicrobial resistance detection software designed to provide fast and accurate annotations for gram-negative bacterial DNA sequences. The company, an EdenRoc Sciences subsidiary co-founded by Stanford and Harvard professors, aims to revolutionize pathogen detection to help combat global infectious disease challenges.